Molecular diagnosis of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

BMC Endocr Disord. 2020 Nov 9;20(1):165. doi: 10.1186/s12902-020-00643-z.

Abstract

Background: Congenital adrenal hyperplasia (CAH) is an autosomal recessive group of diseases. 21-Hydroxylase deficiency (21OHD) accounts for between 95 and 99% of all CAH cases.

Objectives: To characterize the genotype of patients clinically diagnosed with 21OHD and to identify the most frequent mutations in the Cuban population.

Methods: Cross-sectional descriptive study that included all patients diagnosed with 21OHD from January 2000 to December 2018. For the molecular analysis of the CYP21A2 gene, a protocol was used that used the polymerase chain reaction in 2 stages; in the first stage genomic DNA was amplified and 5 point mutations were detected in the second stage (Intron 2, Deletion of 8 bp, G318X, I172N and P30L).

Results: The 5 point mutations were identified in 31 of the 55 (56%) studied patients, 16/21 (76%) in the salt-wasting, 12/18 (67%) in the simple virilizing and 3/16 (19%) in the nonclassical form. The Intron 2 mutation was the most frequent, followed by G318X and 8 bp deletion. Compound heterozygotes were found in 10 patients, all corresponded to classic forms of the disease.

Conclusions: The causal CYP21A2 gene mutation was detected in 56% (72% in classic CAH), which makes the method encouraging. The most frequent mutations observed were Intron 2 and G318X. The detection of mutations offers confirmation of diagnosis, prediction of phenotype and genetic counseling.

Keywords: Congenital adrenal hyperplasia; Genetics; Point mutations.

MeSH terms

  • Adrenal Hyperplasia, Congenital / complications
  • Adrenal Hyperplasia, Congenital / diagnosis*
  • Adrenal Hyperplasia, Congenital / etiology
  • Adrenal Hyperplasia, Congenital / metabolism
  • Biomarkers / analysis*
  • Cross-Sectional Studies
  • Female
  • Follow-Up Studies
  • Genotype
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Mutation*
  • Phenotype*
  • Prognosis
  • Steroid 21-Hydroxylase / genetics*

Substances

  • Biomarkers
  • CYP21A2 protein, human
  • Steroid 21-Hydroxylase

Supplementary concepts

  • Congenital adrenal hyperplasia due to 21 hydroxylase deficiency